The global idiopathic pulmonary fibrosis market size was valued at USD 4.54 billion in 2024 and is projected to reach from ...

In March 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the safety, and tolerability and efficacy ...

The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, reflecting a Compound Annual Growth Rate (CAGR) of 21.6% from 2024 to 2032. Cystic ...

The company's IPO follows a $182m Series C funding round last year.

The Cystic Fibrosis Therapeutics Market Research Report for 2025 delivers a comprehensive analysis of the industry's progress, examining both historical trends and the current market landscape. It ...

Vertex Pharmaceuticals dominates the cystic fibrosis market and has multiple growth drivers. Pfizer is a great pick for both income and value investors. Looking for a good area in which to invest?

The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...

Activity (necroinflammation) and fibrosis are two major histologic features of chronic hepatitis C included in different proposed classifications. One of the few validated scoring systems is ...